



# Explore an Innovative Radiation Therapy Platform

Xoft<sup>®</sup> Axxent<sup>®</sup> Electronic Brachytherapy (eBx<sup>®</sup>) System<sup>®</sup>





Precision therapy.  
Personalized care.


**For us, it's personal.**

We share your passion for targeted cancer care expertly tailored to meet your patients' personalized needs. We designed the Xoft® Axxent® Electronic Brachytherapy (eBx®) System® to empower physicians with full confidence to precisely and effectively treat cancer and enable their patients to live healthy, high-quality lives.

Our versatile Xoft System utilizes high dose rate, low energy electronic brachytherapy to provide expanded treatment options for a range of cancers. With the Xoft System, highly focused therapeutic radiation of the disease target is possible in a minimally shielded setting, while sparing surrounding healthy tissue. Our commitment to this innovative technology is driven by the valuable benefits it offers to you, your facility and your patients.



# A clinical breakthrough for your practice



Our transformative vision for the future of radiation therapy began with the breakthrough development of our miniaturized x-ray source – so small, it could fit on the tip of your finger. Today, this proprietary technology, combined with the comprehensive capabilities of the Xoft System, has powered the treatment of thousands of cancer patients worldwide.

Every component of our advanced platform technology has been expertly engineered to improve quality of care, optimize operational workflow, and increase access to patient-centric, cutting-edge radiation therapy for patients and providers alike – all in one, innovative system.



## Targeted

A miniaturized x-ray source delivers a **precise** dose of radiation directly to the cancerous site. This **focused** approach carefully destroys cancer cells and **saves surrounding healthy tissue**.



## Mobile

Weighing approximately 200 pounds with a **small** footprint, the Xoft System is highly mobile and **portable**, allowing treatment in a wide range of clinical settings.



## Versatile

The Xoft System is FDA cleared, CE marked, and licensed in a growing number of countries for the treatment of cancer **anywhere in the body**, including early-stage breast cancer, non-melanoma skin cancer, and gynecological cancers. Indications currently under investigation also include prostate, pancreatic, colorectal and brain cancers.

Fast dose fall-off enables treatment in a standard room with **minimal shielding requirements**.



## Efficient

Our advanced yet simplified radiation therapy platform empowers you to **streamline** your workflow and **accelerate** installation, training and treatment times. Our **value-based** technology also offers the opportunity to **reduce costs** for both physicians and patients.

# Exceptional clinical innovation at your fingertips

Our passion for targeted cancer care starts at the source.

Our proprietary, miniaturized x-ray source is isotope-free and operates at 50 kV to deliver high dose rate, low energy radiation. The source is placed inside the applicator and energized to deliver a precise, prescribed dose of radiation.

Our versatile Xoft System utilizes electronic brachytherapy to provide expanded treatment options for a range of cancers. The Xoft System is FDA cleared, CE marked, and licensed in a growing number of countries for the treatment of cancer anywhere in the body, including early-stage breast cancer, non-melanoma skin cancer, and gynecological cancers. Indications currently under investigation also include prostate, pancreatic, colorectal and brain cancers.

**Flexible arm**  
facilitates pullback  
positioning

**Bar code scanner**  
streamlines accurate  
data entry

**Fast dose fall-off**  
enables treatment  
in a standard  
operating room with  
**minimal shielding**  
requirements



**Touch screen panel** offers  
easy-to-read, step-by-step  
instructions and real-time  
treatment information

**USB connector** communicates  
individualized treatment plan

Weighing approximately  
**200 pounds** with a  
small footprint, the Xoft  
System is highly **mobile**  
and **portable**

## Axxent Accessories




**Axxent Balloon Applicators**



**Axxent Surface Applicators**



**Axxent Vaginal Applicators**



**Axxent Cervical Applicator**





100% of patients in a clinical study were very pleased with the Xoft breast IORT treatment experience and outcome on follow up visits.<sup>7</sup>

# Intraoperative Radiation Therapy

Weeks of traditional radiation post-lumpectomy present a variety of challenges and stressors for many patients. This may result in patients electing a mastectomy rather than breast-conserving surgery, or failing to comply with follow-up treatment.<sup>1,2</sup>

Xoft offers patients and clinicians a **simplified** alternative to traditional six-week radiation therapy for early-stage breast cancer treatment. With the Xoft System, delivery of radiation therapy in the operating room **at the time of surgery** is possible with intraoperative radiation therapy (IORT).

With IORT, radiation therapy can be adapted to the **personalized** needs of the patient. IORT with the Xoft System provides a **targeted, 1-day** treatment solution delivered in minutes at the time of lumpectomy, **minimizing exposure** to surrounding healthy tissue such as the heart, lungs and ribs.

This quickly streamlines the delivery of care, improving patient **compliance, satisfaction** and **quality of life**, as well as positioning both you and your facility as a provider of **innovative, leading-edge** medicine.

IORT may be utilized to deliver a **single fraction** or **boost** dose. Indications currently under investigation include prostate, pancreatic, colorectal and brain cancers.

A growing body of favorable **clinical data** supports the use of IORT in patients meeting specific selection criteria.<sup>3-6</sup>



# Skin eBx

While Mohs surgery is considered to be the standard of care for non-melanoma skin cancer (NMSC) treatment, for some patients, surgery is not an option or a preference.


Xoft offers patients and physicians a **non-invasive alternative** to surgery for NMSC treatment. With the Xoft System, **painless, scar-free** treatment of NMSC is possible with skin eBx, a form of high dose rate, low energy radiation therapy delivered in **minutes** over a short series of office visits.

From a leading provider in skin electronic brachytherapy, skin eBx provides an **effective, non-surgical, convenient** treatment option with **excellent** clinical and cosmetic results for appropriately selected patients.<sup>8</sup>

Skin eBx is particularly **ideal** in treating **anatomically challenging locations**, such as the face, scalp, nose, ears, arms and legs, as well as areas prone to difficulties in wound healing. Skin eBx may also be the preferred option for patients who are not surgical candidates due to medical comorbidities, or patients with higher-risk lesions requiring adjunct therapy to surgery.

Our skin eBx platform comprised of cutting-edge hardware and software was expertly designed to facilitate best in class **clinical collaboration** and **quality of care**. Our Wi-Fi enabled Xoft System powered by Axxent Hub cloud software provides an **automated** method for managing operational aspects of your skin eBx program, offering a **streamlined workflow** solution.

A growing body of favorable **clinical data** supports the use of skin eBx in patients meeting specific selection criteria.<sup>8-12</sup>



100% of patients in a clinical study agreed that skin eBx was convenient and 96% of patients were satisfied with how well the treatment worked.<sup>13</sup>





“

“ *The Xoft System is able to precisely target cancer cells and spare surrounding healthy tissue, resulting in a significant reduction in the radiation dose that reaches organs at risk. Our early results with this targeted technology are very promising, and we are pleased to offer this valuable treatment option to appropriately selected patients with endometrial and cervical cancer.* ”

– Agustina Mendez Villamon, MD  
Radiation Oncologist  
Miguel Servet University Hospital,  
Zaragoza, Spain

## GYN eBx

With a range of expertly designed applicators for both **endometrial** and **cervical** cancer, **simplified, targeted** radiation therapy for gynecological cancer treatment in a **minimally shielded setting** is possible with GYN electronic brachytherapy (eBx).

Our gynecological applicators provide a therapeutic dose of **isotope-free** radiation therapy for intracavitary treatment of cancer of the uterus, cervix, endometrium and vagina, while **minimizing exposure** to surrounding healthy tissue such as the bladder and rectum.

By providing select gynecological cancer patients with a **concentrated** dose of electronic brachytherapy directly to the tumor site, our high dose, low energy technology offers an **accelerated** course of treatment as compared to traditional radiation therapy.

By **streamlining** the delivery of care, GYN eBx offers increased patient **compliance** and **satisfaction**, and positions both you and your facility as a front-runner providing **advanced** cancer therapies.

A growing body of favorable **clinical data** supports the use of GYN eBx in patients meeting specific selection criteria.<sup>14-20</sup>





# A trusted partner for lasting success

Our commitment to delivering quality patient care spans beyond our state-of-the-art technology. In addition to innovative, personalized treatment options, Xoift is pleased to offer you and your team expert training and support.

## Training & Clinical Support

Comprehensive product training including clinical best practices offers valuable guidance to you and your team.

## Marketing

Our Marketing Assistance Program (**MAP**) is designed to help you establish and grow your eBx practice. Through MAP, you will benefit from a complete package of customizable marketing materials and educational resources developed to support eBx at your facility.

## Technical Support

Our professional services organization guides each practice through the program development process from beginning to end, assisting your practice with the necessary steps to successfully implement eBx at your facility.

## Reimbursement Support Services

Our dedicated team of reimbursement experts can provide answers to questions related to coding, billing and claims.

References: 1. William F. Athas, et al. New Mexico Tumor Registry, University of New Mexico Health Sciences Center, Albuquerque. Travel Distance to Radiation Therapy and Receipt of Radiotherapy Following Breast-Conserving Surgery. *Journal of the National Cancer Institute*, Vol. 92, No. 3, February 2, 2000. 2. Vaidya A, et al. PCN148 Cost Effectiveness Analysis of Targeted Intraoperative Radiotherapy Alone (TARGIT-A) in Early Breast Cancer Patients: Value In Health 17 (2014) A323–A686. TARGIT-A Trial performed with Carl Zeiss Meditec AG IntraBeam System. 3. Vaidya A, et al. Risk-adapted targeted intraoperative radiotherapy versus wholebreast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. *The Lancet*. Volume 383, No. 9917, p603–613. 15 February 2014. TARGIT-A Trial performed with Carl Zeiss Meditec AG IntraBeam System. 4. Syed N, et al. Two-year Follow-up Results of a Multi-center Trial of Intra-operative Electronic Brachytherapy During Breast Conservation Surgery for Early Stage Breast Cancer. Presented at San Antonio Breast Cancer Symposium 2016. 5. Epstein M, et al. Acute and Chronic Complications in Breast Cancer Patients Treated with Intraoperative Radiation Therapy. *Ann Surg Oncol*. 2016 Oct;23(10):3304-9. 6. M Silverstein, et al. Intraoperative Radiation Using Low-Kilovoltage X-Rays for Early Breast Cancer: A Single Site Trial. *The Annals of Surgical Oncology*; August 2017 Online. 7. Proulx G. Intraoperative Radiation (IORT) as Adjuvant Radiation Monotherapy for Early Stage Breast Cancer Patients Treated with Breast Conserving Surgery. Presented at the American Brachytherapy Society Annual Meeting 2017. 8. A Bhatnagar, et al. High-dose Rate Electronic Brachytherapy: A Nonsurgical Treatment Alternative for Nonmelanoma Skin Cancer. *The Journal of Clinical and Aesthetic Dermatology*; Nov. 2016; Vol. 9; No.11: 16-22. 9. R Patel, et al. Comparison of electronic brachytherapy and Mohs micrographic surgery for the treatment of early-stage non-melanoma skin cancer: a matched pair cohort study. *J Contemp Brachytherapy* 2017; 9, 3: 1-7. 10. Bhatnagar A. Electronic Brachytherapy for the treatment of non melanoma skin cancer: results up to 4 years. *Int J Radiat Oncol Biol Phys* 2014; 90 Suppl: S756. 11. Doggett S, Brazil J, Limova M et al. Electronic brachytherapy management of atypical fibroxanthoma: report of 8 lesions. *J Contemp Brachytherapy* 2017; 9: 1-3. 12. Paravati AJ, Hawkins PG, Martin AN et al. Clinical and cosmetic outcomes in patients treated with high-dose-rate electronic brachytherapy for nonmelanoma skin cancer. *Pract Radiat Oncol* 2015;5:e659-e664. 13. A Bhatnagar, et al. Clinical Outcomes and Patient Reported Outcomes Following Electronic Brachytherapy for the Treatment of Non-Melanoma Skin Cancer. Presented at the American Society for Radiation Oncology Annual Meeting 2016. 14. S Lozares, et al. Dosimetric Comparison of Brachytherapy Sources for High Dose-Rate Treatment of Endometrial Cancer: Electronic Brachytherapy, 192Ir, and 60Co Sources. Presented at AAPM 2017. 15. S Lozares, et al. Comparison of brachytherapy sources of endometrial cancer: Electronic brachytherapy source and 192Ir. Presented at ESTRO 2017. 16. A Villamon, et al. Acute toxicity results after treatment with Xoift Axxent Electronic Brachytherapy (XB) in patients with endometrial or cervical cancer. Presented at ESTRO 2017. 17. J Thompson. Feasibility of Cervical Brachytherapy with a Novel 50 kV Electronic Brachytherapy Source. Presented at RSNA 2014. 18. M Kamrava, et al. Electronic brachytherapy for postsurgical adjuvant vaginal cuff irradiation therapy in endometrial and cervical cancer: A retrospective study. *Brachytherapy* 12 (2013) 141-147. 19. W Dooley, et al. Use of electronic brachytherapy to deliver postsurgical adjuvant radiation therapy for endometrial cancer: a retrospective multicenter study. *Oncotargets and Therapy* 2010;3 197-203. 20. Dickler, et al. A dosimetric comparison of Xoift Axxent Electronic Brachytherapy and iridium-192 high-dose-rate brachytherapy in the treatment of endometrial cancer. *Brachytherapy* 2008;5.





 101 Nicholson Lane, San Jose, CA 95134  p: 408.493.1500 | f: 408.493.1501  
 xoftinc.com  /xoftinc  @xofticad  /xofticad  /xoft-inc.

©2017 Xoft®, a subsidiary of iCAD. All rights reserved.  
Xoft, the Xoft logo, Axxent, Electronic Brachytherapy System and eBx are registered trademarks of iCAD, Inc.